Prostate cancer is the most common cancer among men and the risk increases with age. Lu-177-PSMA is a theranostic radiopharmaceutical which is used to treat metastatic prostate cancer. Using the PRRT (Peptide Receptor Radionuclide Therapy) technique, this radiopharmaceutical binds to metastatic prostate tumor cells quite intelligently and selectively, so it can destroy them thoroughly. Moreover, due to being a gamma emitter, Lu-177-PSMA can be used for imaging purposes and following up of the treatments.
Pars Isotope Co
Pars Isotope - Model Lu-177-PSMA -Theranostic Radiopharmaceutical for Prostate Cancer Treatment
FromPars Isotope Co
Lu-177-PSMA is a theranostic radiopharmaceutical designed for the treatment of metastatic prostate cancer. Employing the Peptide Receptor Radionuclide Therapy (PRRT) technique, it selectively targets and binds to prostate tumor cells, facilitating the destruction of malignant cells. This unique action stems from its characteristic as a gamma emitter, allowing not only for therapeutic intervention but also for imaging and monitoring of treatment progress. Ideal for precision oncology, Lu-177-PSMA combines targeted therapeutic effectiveness with diagnostic capabilities, playing a crucial role in managing advanced prostate cancer cases by enabling both treatment and detailed imaging follow-up.